argenx(US:ARGX) Globenewswire·2025-10-23 05:00Core Insights - argenx will host a conference call and audio webcast on October 30, 2025, at 1:30 PM CET to discuss its Q3 2025 financial results and provide a business update [1]. Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3]. - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [3]. - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, evaluating its potential in multiple serious autoimmune diseases while advancing several earlier-stage experimental medicines [3].